Cargando…
Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ reply
Autores principales: | Cortegiani, A., Ippolito, M., Einav, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577672/ https://www.ncbi.nlm.nih.gov/pubmed/33158787 http://dx.doi.org/10.1016/j.pulmoe.2020.10.003 |
Ejemplares similares
-
Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
por: Cortegiani, A., et al.
Publicado: (2021) -
Authors’ Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Liu, Bin, et al.
Publicado: (2020) -
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis – Author’s reply
por: Kashour, Tarek, et al.
Publicado: (2021) -
Chloroquine for COVID-19: rationale, facts, hopes
por: Cortegiani, Andrea, et al.
Publicado: (2020) -
‘Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM’ – Author's reply
por: Broman, Niklas, et al.
Publicado: (2022)